<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39374860</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>CD151 identifies an NK cell subset that is enriched in COVID-19 patients and correlates with disease severity.</ArticleTitle><Pagination><StartPage>106304</StartPage><MedlinePgn>106304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2024.106304</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(24)00238-X</ELocationID><Abstract><AbstractText>Severe coronavirus disease 2019 (COVID-19) often leads to acute respiratory distress syndrome and multi-organ dysfunction, driven by a dysregulated immune response, including a cytokine storm with elevated proinflammatory cytokine levels. Natural killer (NK) cells are part of the innate immune system with a fundamental role in the defense against viral infections. However, during COVID-19 acute infection, they exhibit an altered phenotype and impaired functionality contributing to the immunopathogenesis of the disease. In this work, we have studied a cohort of patients with COVID-19 (ranging from mild to severe) by analyzing IL-15, TGF-β, PlGF and GDF-15 plasma levels and performing multiparametric flow cytometry studies. Our results revealed that severe COVID-19 patients exhibited high levels of IL-15, PlGF and GDF-15, along with an enrichment of an NK cell subset expressing the CD151 tetraspanin, which correlated with IL-15 plasma levels and disease severity. In patients, these CD151+ NK cells displayed a more activated phenotype characterized by an increased expression of HLA-DR, CD38 and granzyme B, a distinct receptor repertoire, with lower levels of CD160 and CD31 and higher levels of CD55 and, remarkably, a higher expression of tissue-resident markers CD103 and the NK cell decidual marker CD9. Last of all, in individuals with severe disease, we identified an expansion of a CD151<sup>bright</sup>CD9+ NK cell subset, suggesting that these cells play a specific role in COVID-19. Altogether, our findings suggest that CD151+ NK cells may have a relevant role in COVID-19 immunopathogenesis.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amarilla-Irusta</LastName><ForeName>Ainhoa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zenarruzabeitia</LastName><ForeName>Olatz</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevilla</LastName><ForeName>Arrate</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandá</LastName><ForeName>Víctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez-Pardo</LastName><ForeName>Ainara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Astarloa-Pando</LastName><ForeName>Gabirel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Garay</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Clinical Analysis Service, Cruces University Hospital, OSI Ezkerraldea-Enkarterri-Cruces, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Fernández</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Scientific Coordination Facility, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijide</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Scientific Coordination Facility, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaz-Ayo</LastName><ForeName>Natale</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Scientific Coordination Facility, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arana-Arri</LastName><ForeName>Eunate</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Scientific Coordination Facility, Biobizkaia Health Research Institute, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrego</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Immunopathology Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Electronic address: francisco.borregorabasco@bio-bizkaia.eus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD151</Keyword><Keyword MajorTopicYN="N">CD9</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GDF-15</Keyword><Keyword MajorTopicYN="N">IL-15</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TGF-β</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>19</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39374860</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2024.106304</ArticleId><ArticleId IdType="pii">S0163-4453(24)00238-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle>